Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Boehringer"

87 News Found

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
Biopharma | April 03, 2026

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning


FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer
Drug Approval | February 28, 2026

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy


Boehringer Ingelheim India appoints Meenal Gauri as Managing Director
People | February 25, 2026

Boehringer Ingelheim India appoints Meenal Gauri as Managing Director

Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East


Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation
R&D | February 24, 2026

Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation

The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies


FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'
Drug Approval | January 23, 2026

FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'

VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs


Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy
Clinical Trials | January 15, 2026

Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy

The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial


FDA nod to Boehringer Ingelheim’s JASCAYD for progressive pulmonary fibrosis in adults
Drug Approval | December 24, 2025

FDA nod to Boehringer Ingelheim’s JASCAYD for progressive pulmonary fibrosis in adults

The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo


Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection
R&D | December 01, 2025

Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection

Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes


Molcure and Boehringer Ingelheim team up to supercharge antibody discovery with AI
R&D | October 07, 2025

Molcure and Boehringer Ingelheim team up to supercharge antibody discovery with AI

This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery


Boehringer and AnGes sign manufacturing agreement for HGF gene therapy product
Biotech | August 25, 2025

Boehringer and AnGes sign manufacturing agreement for HGF gene therapy product

Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing